Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXLIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a neurostimulation pioneer funds R&D, secures patents and rewards executives can take hours. Nexalin Technology Inc’s breakthrough work on non-invasive brain stimulation scatters risk factors, clinical milestones and FDA correspondence across multiple documents. Investors keep asking, “Where can I find Nexalin Technology Inc quarterly earnings report 10-Q filing details?” or “How do I monitor Nexalin Technology Inc insider trading Form 4 transactions before clinical data drops?” Stock Titan turns every new disclosure into clear insight within minutes.
Our platform ingests each filing the moment it appears on EDGAR and delivers concise, AI-powered summaries. Need the Nexalin Technology Inc annual report 10-K simplified to locate device revenue? Seeking a Nexalin Technology Inc proxy statement executive compensation table to gauge leadership incentives? Both arrive pre-highlighted. Real-time alerts flag Nexalin Technology Inc Form 4 insider transactions real-time, while trend charts surface shifts identified in each Nexalin Technology Inc earnings report filing analysis. See also our guide on understanding Nexalin Technology Inc SEC documents with AI.
- Nexalin Technology Inc 8-K material events explained in minutes
- Nexalin Technology Inc SEC filings explained simply with AI-guided notes
- Downloadable exhibits for patent assignments and clinical trial agreements
Use these insights to track FDA milestones, compare R&D spend to cash on hand or follow Nexalin Technology Inc executive stock transactions Form 4 for early signals of management confidence. Professionals analysing neuro-device equities save hours, gain context and react faster—all from one continuously updated page of comprehensive SEC disclosures.
Nexalin Technology, Inc. reported material operational and governance details showing continued cash consumption alongside recent equity raises and Nasdaq compliance. The company lost $7.8 million from operations in 2024 and generated negative operating cash flow of $3.94 million, though it reported a working capital surplus of approximately $3.4 million. Shares outstanding increased to 13,303,523 from 7,436,562, including issuance of 3,000,000 shares to investors for net proceeds of $4.52 million and multiple share issuances to Wider and consultants for services and R&D.
The filing discloses internal control weaknesses: insufficient segregation of duties in financial reporting and inadequate IT user/superuser access controls. The company invested $96,000 in a joint venture accounted for under the equity method and wrote off a previously defaulted promissory note principal of $500,000. On July 23, 2024 Nasdaq confirmed compliance with the Minimum Stockholder Equity Rule.
Nexalin Technology, Inc. (symbol NXLIW) is the subject of a Form 25 notification filed under the Securities Exchange Act to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing names the issuer and provides its principal office at 1776 Yorktown, Suite 550, Houston, Texas 77056 and a contact telephone number as listed in the form.
The document duplicates the regulatory checkboxes for rule provisions governing removal and states that Nasdaq certifies it has complied with the applicable procedures to strike or withdraw the class of securities. The form includes the standard OMB approval legend and a note that the Form 25 and attached notice comply with the applicable rules.
FAQ
What is the current stock price of Nexalin Tech (NXLIW)?
